newsEC approves Vidaza as a new treatment for elderly patients with AML30 October 2015 | By Victoria WhiteDr Hervé Dombret says the 'announcement brings hope to patients with AML, particularly the elderly and more frail patients who cannot undergo intensive therapies'...
newsCelgene announces maintenance results for Ozanimod in ulcerative colitis20 October 2015 | By Victoria WhiteIn the trial, a significantly greater proportion of patients on Ozanimod achieved or maintained clinical remission at 32 weeks compared with those on placebo...
newsCHMP adopts positive opinion of azacitidine for elderly patients with AML25 September 2015 | By Victoria WhiteThe CHMP adopted a positive opinion for an expanded indication of azacitidine for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia who are not eligible for haematopoietic stem cell transplantation...
newsNICE says ‘no’ to apremilast for psoriatic arthritis3 September 2015 | By Victoria WhiteNICE has published final draft guidance which does not recommend apremilast, saying that there is not enough evidence to demonstrate apremilast slows progression of psoriatic arthritis...
newsCelgene completes acquisition of Receptos for $7.2 billion28 August 2015 | By Victoria WhiteCelgene has completed its acquisition of Receptos, significantly enhancing Celgene’s Inflammation & Immunology pipeline with the addition of Ozanimod...
newsCelgene to acquire Receptos for $7.2 billion15 July 2015 | By Victoria WhiteCelgene and Receptos have signed a definitive agreement in which Celgene has agreed to acquire Receptos for approximately $7.2 billion...
newsResults from analyses of REVLIMID MCL-002 (SPRINT) study presented at EHA 201515 June 2015 | By Victoria WhiteAnalyses of Celgene’s MCL-002 study, comparing Revlimid with investigators' choice in MCL, were presented at the European Haematology Association congress...
newsUpdated results from Celgene’s FIRST Study of REVLIMID presented at European Haematology Association congress12 June 2015 | ByCelgene International has announced updated results of its pivotal Phase III FIRST trial of REVLIMID at the European Haematology Association annual congress...
newsPhase II data for GED-0301 in patients with active Crohn’s disease presented at Digestive Disease Week19 May 2015 | By Victoria WhiteA post-hoc subgroup analysis of a Phase II trial of Celgene’s GED-0301 in patients with active Crohn's disease was presented at Digestive Disease Week...
newsFDA Fast Track designation granted to luspatercept for the treatment of patients with beta-thalassemia18 May 2015 | By Victoria WhiteThe FDA has granted Fast Track designations to luspatercept for two separate indications for the treatment of patients with beta-thalassemia...
newsPhase II data for apremilast in Behçet’s disease published16 April 2015 | By Victoria WhiteResults from a multicentre, randomized, placebo-controlled phase II trial (BCT-001) of apremilast in patients with Behçet's disease have been published...
newsPhase II data for Celgene’s investigational Oral GED-0301 for patients with active Crohn’s Disease published19 March 2015 | By VictoriaCelgene Corporation announce results from a phase II trial of GED-0301 on patients with active Crohn's Disease have been published...
newsCelgene’s Otezla® (Apremilast) receives European Marketing Authorisation19 January 2015 | By CelgeneAn oral therapy for moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis, with no drug-specific pre-screening or laboratory monitoring requirements...
newsCelgene receives positive CHMP opinion for OTEZLA® (apremilast)24 November 2014 | By Celgene International SàrlCelgene receives positive CHMP opinion for OTEZLA® (apremilast), the first oral PDE4 inhibitor for the treatment of patients with psoriasis and psoriatic arthritis...
newsOral apremilast significantly improved nail and scalp psoriasis and health-related quality of life measures in phase III esteem 1 study3 October 2013 | By CelgenePsoriasis of the scalp, another difficult-to-treat area, was also improved by treatment with apremilast 30 mg BID...